Heads of HTA Agencies Group convene in Lisbon for fourth meeting

By HEOR Staff Writer

January 18, 2023

HTA Agencies Meeting Updates

HTA Agencies Meeting Updates: It seems the Heads of HTA Agencies Group had a productive meeting in Lisbon, Portugal. They discussed key strategic topics including the confirmation of the new Vice-Chair, updates on the HTA Regulation and long-term strategic planning for the group!

Next meeting will take place in Stockholm, Sweden in May 2023.

Reference url

Recent Posts

trastuzumab-deruxtecan reimbursement
Trastuzumab-Deruxtecan Reimbursement: A Careful Evaluation of Cost-Effectiveness for Advanced Gas...

By João L. Carapinha

May 22, 2026

Zorginstituut Nederland advises against routine trastuzumab-deruxtecan reimbursement for adults with HER2-positive gastric or gastro-oesophageal junction adenocarcinoma after two or more prior therapies, unless price negotiations secure at least a 62 percent reduction. The drug meets scientific s...
Portugal health spending 2025
Portugal Health Spending 2025 Reaches Record €4.417 Billion Amid Rising Demand
Portugal health spending 2025 hit a fresh peak as the country’s publicly funded National Health Service recorded its highest annual outlay on medicines, reaching €4.417 billion according to Infarmed data. This total, already net of industry rebates and contributions, was propelled chiefly by expa...
First-in-Human Trials
First-in-Human Trials: Foundations and Market Implications in Health Economics

By HEOR Staff Writer

May 21, 2026

First-in-Human Trials mark the initial transition of a drug candidate from extensive preclinical research into human subjects, supplying the earliest clinical evidence on safety, pharmacokinetics, and pharmacodynamics to inform later development stages. These studies rely on a comprehensive found...